Hangzhou Tongee Medical Technology Co., Ltd, a Chinese device maker specializing in metabolic disease treatments, has secured close to RMB 100 million (USD 14.9 million) in a Series B financing round. The funding, led by Topping Capital and Guolian Group, will support a regulatory clinical study for its gastric bypass stent system and drive new product development.
Funding and Utilization
The proceeds from this Series B round will be primarily allocated to a regulatory clinical study for Tongee’s gastric bypass stent system, a Category III product with special review status. Additionally, the funds will be used to advance new product research and development and support ongoing clinical trials.
Company Background and Product Pipeline
Founded in 2016, Tongee Medical has established itself as an innovator in the field of metabolic disease treatment. The company’s gastric bypass stent system, designed to treat obesity, type 2 diabetes, and nonalcoholic fatty liver disease, has entered the late-stage follow-up phase of its clinical study. This product exemplifies Tongee’s commitment to developing novel medical devices that address significant unmet needs in metabolic healthcare.-Fineline Info & Tech
